| Factors underlying the Long-term Efficacy of Faecal Microbiota Transplantation for Patients with Irritable Bowel Syndrome M El-Salhy, OH Gilja, JG Hatlebakk Microbes and Infection, 105372, 2024 | | 2024 |
| Increasing the transplant dose and repeating faecal microbiota transplantation results in the responses of male patients with IBS reaching those of females M El-Salhy, OH Gilja, JG Hatlebakk Scandinavian Journal of Gastroenterology 59 (4), 391-400, 2024 | | 2024 |
| Factors Underlying the Difference in Response to Fecal Microbiota Transplantation Between IBS Patients with Severe and Moderate Symptoms M El-Salhy, JG Hatlebakk Digestive Diseases and Sciences 69 (4), 1336-1344, 2024 | | 2024 |
| Quality of life, functional impairment and healthcare experiences of patients with irritable bowel syndrome in Norway: An online survey M El-Salhy, M Johansson, M Ekelund, JG Hatlebakk | | 2024 |
| Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome M El‐Salhy, OH Gilja, JG Hatlebakk Neurogastroenterology & Motility 36 (1), e14641, 2024 | 6 | 2024 |
| A step forward towards a standard FMT protocol for IBS M El‐Salhy, OH Gilja, JG Hatlebakk Alimentary Pharmacology & Therapeutics 58 (10), 1115-1116, 2023 | | 2023 |
| Intestinal bacteria associated with irritable bowel syndrome and chronic fatigue M El‐Salhy Neurogastroenterology & Motility 35 (9), e14621, 2023 | 9 | 2023 |
| Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation M El-Salhy, R Winkel, C Casen, T Hausken, OH Gilja, JG Hatlebakk Gastroenterology 163 (4), 982-994. e14, 2022 | 49 | 2022 |
| The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms M El-Salhy, T Mazzawi, T Hausken, JG Hatlebakk Scandinavian Journal of Gastroenterology 57 (9), 1036-1045, 2022 | 12 | 2022 |
| Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation M El‐Salhy, T Mazzawi, T Hausken, JG Hatlebakk Neurogastroenterology & Motility 34 (9), e14353, 2022 | 9 | 2022 |
| Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation T Mazzawi, T Hausken, M El-Salhy Scandinavian Journal of Gastroenterology 57 (7), 792-796, 2022 | 10 | 2022 |
| Long‐term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome M El‐Salhy, AB Kristoffersen, J Valeur, C Casen, JG Hatlebakk, OH Gilja, ... Neurogastroenterology & Motility 34 (1), e14200, 2022 | 45 | 2022 |
| Current status of fecal microbiota transplantation for irritable bowel syndrome M El‐Salhy, T Hausken, JG Hatlebakk Neurogastroenterology & Motility 33 (11), e14157, 2021 | 38 | 2021 |
| The long-term efficacy and adverse events of fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS) M El-Salhy, C Casen, T Hausken, JG Hatlebakk NEUROGASTROENTEROLOGY AND MOTILITY 33, 2021 | | 2021 |
| Inhibition of cellular and animal inflammatory disease models by NF-κB inhibitor DHMEQ J Ma, Y Zhang, T Sugai, T Kubota, H Keino, M El-Salhy, M Ozaki, ... Cells 10 (9), 2271, 2021 | 14 | 2021 |
| The effects of fecal microbiota transplantation on the symptoms and the duodenal Neurogenin 3, Musashi 1, and enteroendocrine cells in patients with diarrhea-predominant … T Mazzawi, M El-Salhy, GA Lied, T Hausken Frontiers in Cellular and Infection Microbiology 11, 524851, 2021 | 10 | 2021 |
| Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome M El-Salhy, C Casen, J Valeur, T Hausken, JG Hatlebakk World Journal of Gastroenterology 27 (18), 2219, 2021 | 48* | 2021 |
| The role of diet in the pathophysiology and management of irritable bowel syndrome M El-Salhy, T Patcharatrakul, S Gonlachanvit Indian Journal of Gastroenterology 40 (2), 111-119, 2021 | 24 | 2021 |
| FMT in IBS: how cautious should we be? M El-Salhy Gut 70 (3), 626-628, 2021 | 10 | 2021 |
| Changes in fecal short‐chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome M El‐Salhy, J Valeur, T Hausken, J Gunnar Hatlebakk Neurogastroenterology & Motility 33 (2), e13983, 2021 | 50 | 2021 |
Odd Helge GiljaProfessor i medisin ved UiB在 uib.no 的电子邮件经过验证
